Gary Jacob - Hepion Pharmaceuticals Chairman of the Board of Directors
| HEPA Stock | USD 1.41 0.60 29.85% |
Chairman
Dr. Gary S. Jacob, Ph.D. is Chairman of the Board of Directors of the Company. Dr. Jacob is served as our Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob is currently the Chairman of the Board, President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he has held various positions since July 2008. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a precision medicine company. Dr. Jacob has over twentyfive years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporationrationrate Science Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. Dr. Jacobs experience as a biotechnology company chief executive officer provides him with valuable management and leadership abilities which the Board believes qualifies him to be a director of our Company. since 2014.
| Age | 70 |
| Tenure | 10 years |
| Address | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Phone | 732 902 4000 |
| Web | https://www.hepionpharma.com |
Gary Jacob Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gary Jacob against Hepion Pharmaceuticals stock is an integral part of due diligence when investing in Hepion Pharmaceuticals. Gary Jacob insider activity provides valuable insight into whether Hepion Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Hepion Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hepion Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gary Jacob over two months ago Acquisition by Gary Jacob of 85000 shares of Hepion Pharmaceuticals subject to Rule 16b-3 |
Hepion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7221) % which means that it has lost $0.7221 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7126) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.57. The current year's Return On Capital Employed is expected to grow to -3.36. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 24 M, whereas Non Currrent Assets Other are forecasted to decline to about 222.4 K.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Alistair Ryan | Evotec SE ADR | N/A | |
| Jay Moorin | Eagle Pharmaceuticals | 62 | |
| Richard Pops | Alkermes Plc | 62 | |
| Ralph Verni | Evotec SE ADR | 73 | |
Management Performance
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.72 |
Hepion Pharmaceuticals Leadership Team
Elected by the shareholders, the Hepion Pharmaceuticals' board of directors comprises two types of representatives: Hepion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hepion. The board's role is to monitor Hepion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hepion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hepion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Adams, Independent Director | ||
| BSc BSc, CEO Pres | ||
| Robert Foster, CEO, Director | ||
| Patrick Mayo, Senior Pharmacology | ||
| Sharen Pyatetskaya, Director Relations | ||
| Timothy Block, Independent Director | ||
| John Brancaccio, Independent Director | ||
| Launa Aspeslet, Chief Officer | ||
| Stephen MD, Member Director | ||
| John Cavan, Chief Officer | ||
| Arnold Lippa, Independent Director | ||
| Todd MD, Chief Officer | ||
| Daniel Trepanier, Senior Development | ||
| Daren Ure, Chief Officer | ||
| MD FACP, Scientific Director | ||
| John SullivanBolyai, Chief Medical Officer | ||
| Gary Jacob, Chairman of the Board of Directors |
Hepion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hepion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | (1.88 M) | ||||
| Shares Outstanding | 5.47 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 13.60 % | ||||
| Number Of Shares Shorted | 62.84 K | ||||
| Price To Earning | (3.01) X | ||||
| Price To Book | 0.67 X | ||||
| EBITDA | (45.19 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hepion Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hepion Pharmaceuticals' short interest history, or implied volatility extrapolated from Hepion Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.